Health Care·Pharmaceuticals·$3.2B
Alumis Inc is a pharmaceutical company operating in the health care sector, focusing on developing innovative treatments. With a market cap of $3 billion, it plays a crucial role in addressing unmet medical needs, which is increasingly important as the demand for effective health solutions grows.
EPS
Earnings per share is a key indicator of profitability and financial health, and investors will be keen to see if the company can narrow its losses this quarter.
Revenue
Revenue figures will provide insight into the company's sales performance and market demand for its products, crucial for assessing growth potential.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
0Q
EPS Beat Rate
0%
Avg EPS Surprise
-1371.34%
Avg Stock Reaction
+4.59%
In the last quarter, Alumis reported a significant earnings miss, with an EPS of $-23.10 compared to an estimate of $-1.57. The stock reacted positively, gaining 4.59% the following day despite the disappointing results.
Management Promises & Guidance
Analysts are expecting another challenging quarter for Alumis, with a consensus EPS loss of $-0.78. Revenue expectations are low, indicating cautious sentiment among investors.
Bull Case
If Alumis can show improved operational efficiencies and a stronger revenue performance, it could signal a turnaround, leading to increased investor confidence.
Bear Case
Continued losses and weak revenue could raise concerns about the company's viability and future growth prospects, leading to further declines in stock price.
EPS
$-0.78Earnings per share is a key indicator of profitability and financial health, and investors will be keen to see if the company can narrow its losses this quarter.
Revenue
$2MRevenue figures will provide insight into the company's sales performance and market demand for its products, crucial for assessing growth potential.
The print will turn on these two things.
Q1
Can Alumis narrow its EPS loss to $-0.78 or better?
A smaller loss would indicate progress in managing costs and could boost investor sentiment.
Q2
Will revenue reach or exceed the $2M consensus?
Meeting or exceeding revenue expectations would suggest stronger market demand and could positively influence the stock.
Why consensus could be wrong
The Street may be underestimating the potential for revenue growth driven by new product launches, which could significantly improve financial performance this quarter.
Supporting Evidence
The previous quarter's stock increase despite a massive EPS miss suggests underlying investor confidence.
Analysts may not fully account for recent positive developments in product pipeline advancements.
Key Risk
If revenue exceeds $2M, it could challenge the current bearish sentiment and shift the narrative toward recovery.
Pre-commit to what would confirm each case.
The core debate this quarter revolves around whether Alumis can show signs of financial recovery or if it will continue to struggle with losses.
Bull Confirmed If
Achieving an EPS loss of $-0.70 or better would confirm the bull case and suggest improved financial health.
Bear Confirmed If
An EPS loss greater than $-0.86 would confirm the bear case, indicating ongoing financial struggles.
Implied Move
±4.2%
The options market is pricing in a relatively modest move, suggesting that investors are uncertain about the company's upcoming performance.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Alumis beats expectations, history suggests the stock could rise by around 4.59%, confirming a positive turnaround narrative.
In-Line / Cautious
An in-line report may lead to a muted reaction as investors await further clarity on future guidance.
Miss
If the company misses expectations, history suggests a potential decline of around 4.59%, raising concerns about its financial stability.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
FRANCO NEV CORP
May 12, 2026